Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Charting the course across the blood-brain barrier
David Nathanson, Paul S. Mischel
David Nathanson, Paul S. Mischel
Published December 22, 2010
Citation Information: J Clin Invest. 2011;121(1):31-33. https://doi.org/10.1172/JCI45758.
View: Text | PDF
Commentary

Charting the course across the blood-brain barrier

  • Text
  • PDF
Abstract

The blood-brain barrier (BBB) presents a significant obstacle to delivery of targeted therapies to brain tumors. In this issue of the JCI, Staquicini and colleagues apply an in vivo phage-displayed library of random peptides to identify differentially expressed peptides that can be used to transport targeted agents across the intact BBB. The authors uncover a non-canonical, peptide-mediated iron-mimicry mechanism to induce transport of the transferrin/transferrin receptor complex across the BBB. They then demonstrate the ability of phage-targeting approaches to deliver therapeutic cargo and molecular imaging reporters across the BBB in an intracranial glioblastoma mouse model.

Authors

David Nathanson, Paul S. Mischel

×

Figure 1

Peptide-mediated iron mimicry transports the transferrin/TfR complex across the BBB, delivering therapeutic and imaging cargo.

Options: View larger image (or click on image) Download as PowerPoint
Peptide-mediated iron mimicry transports the transferrin/TfR complex acr...
The BBB is composed of a variety of cells, including endothelial cells with tight junctions, pericytes, perivascular neurons, and astrocytes. Under normal conditions, the BBB prevents the passage of small molecules into the brain. Receptor-mediated transport allows passage of selected molecules across the BBB. The binding of iron to transferrin induces a conformational shift from the open form of transferrin (Apo-Tf) to the closed form (Halo-Tf), facilitating transport of bound iron-transferrin in complex with TfR across the BBB. The iron peptide mimic CRTIGPSVC specifically binds Tf, enabling transport of the peptide and its cargo in complex with transferrin/TfR across the BBB.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts